Literature DB >> 25404365

OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.

Sarah Buchan1, Teresa Manzo2, Barry Flutter2, Anne Rogel1, Noha Edwards2, Lei Zhang2, Shivajanani Sivakumaran2, Sara Ghorashian2, Ben Carpenter2, Clare Bennett2, Gordon J Freeman3, Megan Sykes4, Michael Croft5, Aymen Al-Shamkhani1, Ronjon Chakraverty2.   

Abstract

Exhaustion of chronically stimulated CD8(+) T cells is a significant obstacle to immune control of chronic infections or tumors. Although coinhibitory checkpoint blockade with anti-programmed death ligand 1 (PD-L1) Ab can restore functions to exhausted T cell populations, recovery is often incomplete and dependent upon the pool size of a quiescent T-bet(high) subset that expresses lower levels of PD-1. In a model in which unhelped, HY-specific CD8(+) T cells gradually lose function following transfer to male bone marrow transplantation recipients, we have explored the effect of shifting the balance away from coinhibition and toward costimulation by combining anti-PD-L1 with agonistic Abs to the TNFR superfamily members, OX40 and CD27. Several weeks following T cell transfer, both agonistic Abs, but especially anti-CD27, demonstrated synergy with anti-PD-L1 by enhancing CD8(+) T cell proliferation and effector cytokine generation. Anti-CD27 and anti-PD-L1 synergized by downregulating the expression of multiple quiescence-related genes concomitant with a reduced frequency of T-bet(high) cells within the exhausted population. However, in the presence of persistent Ag, the CD8(+) T cell response was not sustained and the overall size of the effector cytokine-producing pool eventually contracted to levels below that of controls. Thus, CD27-mediated costimulation can synergize with coinhibitory checkpoint blockade to switch off molecular programs for quiescence in exhausted T cell populations, but at the expense of losing precursor cells required to maintain a response.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25404365      PMCID: PMC4272895          DOI: 10.4049/jimmunol.1401644

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state.

Authors:  Andrea Schietinger; Jeffrey J Delrow; Ryan S Basom; Joseph N Blattman; Philip D Greenberg
Journal:  Science       Date:  2012-01-19       Impact factor: 47.728

Review 2.  Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

Authors:  Andrea Schietinger; Philip D Greenberg
Journal:  Trends Immunol       Date:  2013-11-06       Impact factor: 16.687

3.  Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory.

Authors:  Travis A Doering; Alison Crawford; Jill M Angelosanto; Michael A Paley; Carly G Ziegler; E John Wherry
Journal:  Immunity       Date:  2012-11-15       Impact factor: 31.745

Review 4.  Molecular mechanisms of T cell co-stimulation and co-inhibition.

Authors:  Lieping Chen; Dallas B Flies
Journal:  Nat Rev Immunol       Date:  2013-03-08       Impact factor: 53.106

5.  CD27-CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection.

Authors:  Suzanne P M Welten; Anke Redeker; Kees L Franken; Chris A Benedict; Hideo Yagita; Felix M Wensveen; Jannie Borst; Cornelis J M Melief; René A W van Lier; Klaas P J M van Gisbergen; Ramon Arens
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

6.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

Authors:  Alena Gros; Paul F Robbins; Xin Yao; Yong F Li; Simon Turcotte; Eric Tran; John R Wunderlich; Arnold Mixon; Shawn Farid; Mark E Dudley; Ken-Ichi Hanada; Jorge R Almeida; Sam Darko; Daniel C Douek; James C Yang; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2014-03-25       Impact factor: 14.808

7.  Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Authors:  Michael A Paley; Daniela C Kroy; Pamela M Odorizzi; Jonathan B Johnnidis; Douglas V Dolfi; Burton E Barnett; Elizabeth K Bikoff; Elizabeth J Robertson; Georg M Lauer; Steven L Reiner; E John Wherry
Journal:  Science       Date:  2012-11-30       Impact factor: 47.728

8.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

9.  CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion.

Authors:  Masanori Isogawa; Josan Chung; Yasuhiro Murata; Kazuhiro Kakimi; Francis V Chisari
Journal:  PLoS Pathog       Date:  2013-07-11       Impact factor: 6.823

10.  OX40 facilitates control of a persistent virus infection.

Authors:  Tobias Boettler; Friedrich Moeckel; Yang Cheng; Maximilian Heeg; Shahram Salek-Ardakani; Shane Crotty; Michael Croft; Matthias G von Herrath
Journal:  PLoS Pathog       Date:  2012-09-06       Impact factor: 6.823

View more
  25 in total

1.  Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.

Authors:  Jens Schreiner; Daniela S Thommen; Petra Herzig; Marina Bacac; Christian Klein; Andreas Roller; Anton Belousov; Victor Levitsky; Spasenija Savic; Wolfgang Moersig; Franziska Uhlenbrock; Viola A Heinzelmann-Schwarz; Pablo Umana; Pavel Pisa; M von Bergwelt-Baildon; Didier Lardinois; Philipp Müller; Vaios Karanikas; Alfred Zippelius
Journal:  Oncoimmunology       Date:  2015-06-24       Impact factor: 8.110

Review 2.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 3.  Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.

Authors:  Yi Xia; L Jeffrey Medeiros; Ken H Young
Journal:  Biochim Biophys Acta       Date:  2015-10-16

4.  Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Authors:  Ludmila Danilova; Hao Wang; Joel Sunshine; Genevieve J Kaunitz; Tricia R Cottrell; Haiying Xu; Jessica Esandrio; Robert A Anders; Leslie Cope; Drew M Pardoll; Charles G Drake; Janis M Taube
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

5.  CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.

Authors:  Pablo Penaloza-MacMaster; Nicholas M Provine; Eryn Blass; Dan H Barouch
Journal:  J Immunol       Date:  2015-06-26       Impact factor: 5.422

Review 6.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

7.  Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

Authors:  David J Messenheimer; Shawn M Jensen; Michael E Afentoulis; Keith W Wegmann; Zipei Feng; David J Friedman; Michael J Gough; Walter J Urba; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2017-08-28       Impact factor: 12.531

8.  Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.

Authors:  Mengjia Song; Xinfeng Chen; Liping Wang; Yi Zhang
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

9.  PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.

Authors:  Sarah L Buchan; Mohannad Fallatah; Stephen M Thirdborough; Vadim Y Taraban; Anne Rogel; Lawrence J Thomas; Christine A Penfold; Li-Zhen He; Michael A Curran; Tibor Keler; Aymen Al-Shamkhani
Journal:  Clin Cancer Res       Date:  2018-03-07       Impact factor: 12.531

10.  Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation.

Authors:  Alyssa K Kosmides; Kevin Necochea; John W Hickey; Jonathan P Schneck
Journal:  Nano Lett       Date:  2018-02-28       Impact factor: 11.189

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.